Multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain.

Trial Profile

Multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Oxycodone/naloxone (Primary)
  • Indications Pain
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Mundipharma GmbH
  • Most Recent Events

    • 20 Oct 2015 Results published in Mundipharma media release.
    • 20 Oct 2015 Primary endpoint has not been met, as per Mundipharma media release.
    • 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top